Inno TCR-T- ESO cell therapy

因诺替西尔替-ESO细胞疗法

Report date: 2023/02/10 17:26:52

Base Information

Drug NameInno TCR-T- ESO cell therapy
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-NY-ESO-1
TargetsCancer/testis antigen 1
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesShenzhen Inno Immunization Co LtdHangzhou Chaomei Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHangzhou Chaomei Biotechnology Co LtdShenzhen Inno Immunization Co Ltd
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A